Literature DB >> 25757630

Labyrinthitis Ossificans: On the Mechanism of Perilabyrinthine Bone Remodeling.

Sune Land Bloch1, Michael John McKenna2, Joe Adams2, Morten Friis3.   

Abstract

INTRODUCTION: It has been suggested that remodeling of the otic capsule is highly suppressed by the action of anti-resorptive signals emanating from structures of the inner ear space. Labyrinthitis ossificans (LO) is a severe complication to bacterial meningitis and is characterized by destruction of inner ear structures by the formation of new bone. The aim of this study was to explore the impact of LO on bone remodeling of the otic capsule.
MATERIAL AND METHODS: In 11 human temporal bones with extensive LO and 10 control specimens, the degree of bone remodeling was explored indirectly by estimating the viability of osteocytes in perilabyrinthine bone and the mastoid.
RESULTS: The viability of osteocytes was significantly lower in the perilabyrinthine bone compared to the mastoid in both groups. However, the loss of perilabyrinthine osteocytes was the same in the 2 groups, and the presence of cartilage remnants appeared to be the same.
CONCLUSION: This study indicates that the factors affecting bone remodeling of the otic capsule and the degeneration of osteocytes are not altered by wholesale destruction of inner ear soft tissue and its replacement by bone. Therefore, alternative mechanisms may be implicated in the suppression of capsular bone remodeling.
© The Author(s) 2015.

Entities:  

Keywords:  anti-resorptive barriers; cartilage remnants; lining cells; osteocytes; osteoprotegerin

Mesh:

Year:  2015        PMID: 25757630     DOI: 10.1177/0003489415573960

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  1 in total

Review 1.  Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review.

Authors:  F A Diepstraten; A E Hoetink; M van Grotel; A D R Huitema; R J Stokroos; M M van den Heuvel-Eibrink; A J M Meijer
Journal:  JAC Antimicrob Resist       Date:  2021-12-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.